• 1
    Tabár L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, et al. Efficacy of breast cancer screening by age: new results from the Swedish Two-County Trial. Cancer 1995; 75: 250717.
  • 2
    Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of the Swedish randomized trials. Lancet 1993; 341: 9738.
  • 3
    Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997; 22: 8792.
  • 4
    Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 1989; 59: 9548.
  • 5
    Sjönell G, Ståhle L. Hälsokontroller med mammografi minskar inte dödlighet I bröstcancer. Läkartidningen 1999; 96: 90413.
  • 6
    Rosen M, Rehnqvist N. Breast screening. BMJ 1999; 318: 880910.
  • 7
    Sjönell G, Ståhle L. Scientific foundation of mammographic screening is based on inconclusive research in Sweden. BMJ 1999; 319(3 July): 55.
  • 8
    Tabár L, Duffy SW. Criticism of Swedish mammography trials were wrong. BMJ 1999; 319(20 Nov): 1367.
  • 9
    Tabár L, Fagerberg G, Duffy SW, Day NE, Gad A, Gröntoft O. Update of the Swedish Two-County program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30: 187210.
  • 10
    Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, et al. The Swedish Two-County Trial twenty years later: updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000; 38: 62551.
  • 11
    Breslow NE, Day NE. Statistical methods in cancer research. Vol. II. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987.
  • 12
    Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: earlier diagnosis and better treatment. BMJ 1997; 314: 4725.
  • 13
    Chen HH, Duffy SW, Tabár L, Day NE. Markov chain models for progression of breast cancer. Part 1: tumour attributes and the preclinical detectable phase. J Epidemiol Biostat 1997;2: 923.
  • 14
    Baum M. Screening mammography re-evaluated. Lancet 2000; 355: 751.
  • 15
    Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales 1990-8: comparison of observed with predicted mortality. BMJ 2000; 321: 6659.
  • 16
    Sundqvist M. Incidence and prognosis in early-onset breast cancer [M.D. thesis]. Linköping, The Netherlands: University of Linköping, 2000.
  • 17
    van den Akker-van Marle E, de Koning H, Boer R, van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: comparison with the United Kingdom. J Med Screen 1999; 6: 304.
  • 18
    Fracheboud J, de Koning HJ, Beemsterboer PMM, Boer R, Verbeek AL, Hendricks JH, et al. Interval cancers in the Dutch breast cancer screening programme. Br J Cancer 1999; 81: 9127.
  • 19
    McCann J, Stockton D, Day NE. Breast cancer in East Anglia: the impact of the breast cancer screening program on stage at diagnosis. J Med Screen 1998; 5: 428.
  • 20
    Tabár L, Dean PB, Kaufman CS, Duffy SW, Chen HH. A new era in the diagnosis of breast cancer. Surg Oncol Clin North Am 2000; 9: 23377.
  • 21
    Dean PB, Pamilo M. Screening mammography in Finland–1.5 million examinations with 97 percent specificity. Mammography Working Group, Radiology Society of Finland. Acta Oncol 1999;38(Suppl 13): 4754.
  • 22
    Lidbrink EK, Thörnberg SA, Azavedo EM, Frisell JO, Hjalmar ML, Leifland KS, et al. The general mammography screening program in Stockholm. Organisation and first-round results. Acta Oncol 1994;33(4): 3538.